Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis.

Publication

Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis.

Journal Paper/Review - Mar 1, 2022

Katsanos Aristeidis H, Psychogios Klearchos, Turc Guillaume, Sacco Simona, Maurice De Sousa Dave, De Marchis Gian Marco, Palaiodimou Lina, Filippou Dimitrios K, Ahmed Niaz, Sarraj Amrou, Menon Bijoy K, Tsivgoulis Georgios

Citation

Katsanos A, Psychogios K, Turc G, Sacco S, Maurice De Sousa D, De Marchis G, Palaiodimou L, Filippou D, Ahmed N, Sarraj A, Menon B, Tsivgoulis G. Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e224506.

Type

Journal Paper/Review (English)

Journal

JAMA Netw Open 2022; 5

Publication Date

Mar 1, 2022

Issn Electronic

2574-3805

Pages

e224506

Brief description/objective

Tenecteplase is being evaluated as an alternative thrombolytic agent for the treatment of acute ischemic stroke (AIS) within ongoing randomized clinical trials (RCTs). In addition, nonrandomized clinical experiences with off-label use of tenecteplase vs alteplase for AIS treatment are being published.